Company Filing History:
Years Active: 2014-2021
Title: Innovations by Erik De Leeuw in Antibiotic Development
Introduction
Erik De Leeuw is a prominent inventor based in Baltimore, MD (US), known for his significant contributions to the field of antibiotic research. With a total of four patents to his name, he has focused on developing novel compounds that combat resistant bacterial strains.
Latest Patents
De Leeuw's latest patents include small molecule lipid II inhibitors. Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and combat resistant bacterial strains. These compounds and pharmaceutical compositions are based on a generic scaffold structure. The preferred compound, 6jc48-1, binds to Lipid II with high affinity, exhibits markedly reduced cytotoxicity compared to BAS00127538, and retains activity against drug-resistant strains. It is stable in plasma, has dramatically improved pharmacokinetic and pharmacodynamics properties, and demonstrates in vivo efficacy in a mouse model of sepsis.
Career Highlights
Erik De Leeuw is affiliated with the University System of Maryland, where he continues to advance his research in antibiotic development. His work has the potential to significantly impact the treatment of bacterial infections, particularly those that are resistant to conventional therapies.
Collaborations
Some of his notable coworkers include Alexander D MacKerell, Jr and Alexander MacKerell, who have collaborated with him on various research projects.
Conclusion
Erik De Leeuw's innovative work in developing small molecule lipid II inhibitors showcases his commitment to addressing the challenges posed by antibiotic resistance. His contributions are vital in the ongoing fight against bacterial infections.